Schedule 13G/A

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, J62klzqSuNSJPi7v+NOy/smpagxNXAyV8sA0lty6ZlJDbG9gES5W+5xa09uB3WFn I0TWYIl2RRWkWRu39LiTvQ== 0001193125-06-016940.txt : 20060201 0001193125-06-016940.hdr.sgml : 20060201 20060201110857 ACCESSION NUMBER: 0001193125-06-016940 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20060201 DATE AS OF CHANGE: 20060201 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ESHELMAN FREDRIC N CENTRAL INDEX KEY: 0001033409 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: BUSINESS PHONE: 9102510081 MAIL ADDRESS: STREET 1: PPD INC STREET 2: 3151 17TH STREET EXTENSION CITY: WILMINGTON STATE: NC ZIP: 28412 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: PHARMACEUTICAL PRODUCT DEVELOPMENT INC CENTRAL INDEX KEY: 0001003124 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 561640186 STATE OF INCORPORATION: NC FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-48083 FILM NUMBER: 06568285 BUSINESS ADDRESS: STREET 1: 3151 SOUTH 17TH ST CITY: WILMINGTON STATE: NC ZIP: 28412 BUSINESS PHONE: 9102510081 MAIL ADDRESS: STREET 1: 3151 SOUTH 17TH ST CITY: WILMINGTON STATE: NC ZIP: 28412 SC 13G/A 1 dsc13ga.htm SCHEDULE 13G/A Schedule 13G/A

Page 1

SCHEDULE 13G.

Name of Issuer: Pharmaceutical Product Development, Inc.

Title of Class of Securities: Common Stock

CUSIP Number: 717124101


1.		Names of reporting Persons. S.S. or I.R.S. Identification Nos. of Above Persons. Fredric N. Eshelman
2.		Check the Appropriate Box if a Member of a Group: NOT APPLICABLE (a) ¨ (b) ¨
3.		SEC Use Only:
4.		Citizenship or Place of Organization: United States


Number of Shares Beneficially Owned :		5. Sole Voting Power: 4,954,325
		6. Shared Voting Power: 0
		7. Sole Dispositive Power: 4,954,325
		8. Shared Dispositive Power: 0


9.		Aggregate Amount Beneficially Owned by Each Reporting Person: 4,954,325
10.		Check if the Aggregate Amount in Row (9) Excludes Certain Shares: Not Applicable
11.		Percent of Class Represented by Amount in Row (9): 8.5%
12.		Type of Reporting Person: IN

Page 2

Item 1.

(a)

Issuer

Pharmaceutical Product Development, Inc.

(b)

3151 South 17^th Street

Wilmington, North Carolina 28412

Item 2.

(a)

Person Filing

Fredric N. Eshelman

(b)

Pharmaceutical Product Development, Inc.

3151 South 17^th Street

Wilmington, North Carolina 28412

(c)

United States

(d)

Common Stock

(e)

717124101

Item 3.

Filing Pursuant to Rules 13d-1(b) or 13(d)-2(b)

Not Applicable



Item 4.	Ownership.

	(a)	4,954,325 includes 91,250 shares issuable pursuant to vested options.

	(b)	8.5%

	(c)	The Reporting Person retains sole voting and dispositive power of all shares.

Item 5.	Ownership of Five Percent or Less of Class Not Applicable

Item 6.	Ownership of More than Five Percent on Behalf of Another Person Not Applicable

Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Not Applicable

Item 8.	Identification and Classification of Members of the Group Not Applicable

Item 9.	Notice of Dissolution of Group Not Applicable

Item 10.	Certification Not Applicable

Page 3

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date

Fredric N. Eshelman

/s/ Fred B. Davenport, Jr.

Name: Fred B. Davenport, Jr.

Title: Attorney in Fact*

*	Signed pursuant to a power of attorney, dated December 16, 1998, included as an exhibit to Schedule 13G filed with the Securities and Exchange Commission by Fredric N. Eshelman on February 1, 2006.

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of Rudy C. Howard or Fred B. Davenport, Jr. signing singly, with full power of substitution, his/her true and lawful attorney-in-fact, to execute and cause to be filed and/or delivered, as required under Section 13(d) of the Securities Exchange Act of 1934 (the “Act”) and the regulations thereunder, any number, as appropriate, of original, copies, or electronic filings of the Securities and Exchange Commission Schedule 13G Beneficial Ownership Reports (together with any amendments and joint filing agreements under Rule 13-d-1(f) (1) of the Act, as may be required thereto) to be filed and/or delivered with respect to any equity security (as defined in Rule 13(d)-1(d) under the Act) of Pharmaceutical Product Development, Inc. beneficially owned by the undersigned and which must be reported by the undersigned pursuant to Section 13(d) of the Act and the regulations thereunder, and generally to take such other actions and perform such other things necessary to effectuate the foregoing as fully in all respects as if the undersigned could do if personally present.

This Power of Attorney is governed by and shall be construed in accordance with the laws of the State of North Carolina. This Power of Attorney is effective until revoked by the undersigned, which revocation shall be evidenced by an instrument in writing in form required by North Carolina law. This Power of Attorney is executed pursuant to the provisions of the North Carolina General Statutes, Chapter 32A, Article 2, with the intention that this Power of Attorney and the authority of said attorney-in-fact hereunder shall continue in effect notwithstanding any incapacity or mental incompetence which may be incurred by the undersigned subsequent to the execution of this Power of Attorney by the undersigned.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 16th day of December, 1998.

/s/ Fredric N. Eshelman

-----END PRIVACY-ENHANCED MESSAGE-----